Jeff Farrow
Pulmonary Disease · Johnson City, TNNPI 1942238746
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $123,490 of the $144,210 with a category attached, or 85.6%. 41 manufacturers reported payments, led by GSK at 52.6% of the total. Reporting peaked in 2019 at $35,080 and has fallen 100.0% since, to $10 in 2024. Among pulmonary disease clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 623 payments — averaging $231.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$76K
- Mallinckrodt Hospital Products Inc.$25K
- Mallinckrodt Enterprises LLC$13K
- Boehringer Ingelheim$13K
- Intuitive Surgical$5K
- AstraZeneca$4K
- plus $8K from 35 others
What the payments were for
- Consulting fees$4,8003%
- Speaking & faculty fees$123,49086%
- Travel & lodging$1,7771%
- Food & beverage$10,8998%
- Education$3,2432%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$57,400
- ACTHAR$36,990
- Da Vinci Surgical System$4,398
- TAGRISSO$3,355
- STIOLTO RESPIMAT$1,545
- ANDEXXA$339
- MONARCH$283
- TEZSPIRE$100
- FASENRA$100
- BREZTRI$100
How this compares
$144,210 in reported general payments places this provider in the 95th percentile of 339 pulmonary disease providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $31,125 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $9,201 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $7,470 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,420 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,808 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 47 | $961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $75,911 | $36,54453 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $4,470 | $13,00826 claims |
| Boehringer IngelheimStiolto Respimat | $12,817 | $7,47016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Johnson City
- Celso EbeoJohnson City$18K
- Lisa LancasterNashville$519K
- Krishnendu BhadraChattanooga$494K
- Aaron MilstoneFranklin$482K
- Otis RickmanNashville$392K
- Michael CzarneckiChattanooga$348K
- Susan GarwoodNashville$343K
- Girendra HoskereBristol$285K
- Carlos BaleeiroChattanooga$265K
- Joao DeandradeNashville$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.